Conference Call with Ami Organics Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Ami Organics announced Q3FY25 results Revenue from operations for Q3FY25 grew by 65.2% YoY to Rs 2,750 million. The gross margin for the quarter improved to 46.2% up 333 bps YoY and 281 bps QoQ. EBITDA for the quarter came at Rs 687 million up 159.0% YoY compared to Rs 265 million in Q3FY24. EBITDA margin for the quarter was at 25.0% as compared to 15.9% in Q3FY24. PAT for the quarter was Rs 454 million up 155.1% as compared to PAT of Rs 178 million in Q3FY24. The PAT margin for the quarter was at 16.5% up 582 bps YoY and 130 bps QoQ. Export for the quarter at 76%; domestic business at 24%. Naresh Patel, Executive Chairman & Managing Director, Ami Organics, said: “I am delighted to share that in the first nine months of FY25, we achieved revenue of X698 crore, nearly equalling the revenue from operations of the entire previous financial year. In Q3FY25 alone, we delivered an impressive 65.2% YoY growth, achieving Rs 275 crore in revenue from operations. This performance was driven by a strong ramp-up in our CDMO business and consistent growth in advanced pharmaceutical intermediates. Our pipeline of CDMO projects is progressing well, with several initiatives nearing commercialization by FY26, solidifying the foundation for sustained long-term growth. Ongoing discussions with innovators and partners remain highly encouraging, and we are confident that the CDMO segment will see exponential growth in the coming years. With improved visibility for Q4, | am pleased to revise our FY25 growth guidance upward from 30% to 35%. This milestone reflects our unwavering commitment to delivering consistent progress, embracing adaptability, and seizing new opportunities that ensure sustainable and impactful growth.” Result PDF